Newbury Pharmaceuticals signs 10-year exclusivity deal for 40-product hospital portfolio in Iraq

Bitget2026/09/28 12:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Newbury Pharmaceuticals entered a 10-year exclusivity agreement with a Chinese drug manufacturer covering a 40-product hospital portfolio in Iraq.
Deal grants exclusive rights to register, market, sell products in Iraq under Newbury labels, targeting acute care and injectable medicines.
Portfolio centers on anti-infectives, pain and surgical-support drugs, gastroenterology injectables, supportive care products for hospital tenders, private channels.
Newbury applied for an Iraqi import license that could enable limited early supply ahead of full marketing authorizations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 5th – Elon Musk confirmed discussions with TSMC (2330.TW), prompting a 3% increase in the company’s share price. The Taiwan Stock Exchange Weighted Index (.TWII) rose by 2.4%. Tesla (TELA.O) and SpaceX (SPCX.O) CEO Musk stated on Saturday via X platform that TSMC and his chip manufacturing project, Terafab, have discussed potential collaboration. In response to a post on X featuring a screenshot of an article titled “TSMC is exploring plans to cooperate with Elon Musk’s TeraFab,” Musk replied on Saturday: "It is only at the discussion stage for now, but something could result." TSMC’s share price has increased by 66% so far this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack needed context, Reuters does not guarantee the accuracy of the automated translated texts. They are provided merely for the convenience of readers. Reuters bears no responsibility for any damage or losses resulting from the use of the automated translation function.)

路透社•2026/10/05 02:16